Bayer May Not Launch In Innovation-Unfriendly European Markets
Concerns Growing Over Current Environment
Executive Summary
The attractiveness of investing in R&D and launching new products in Europe is wearing off, especially when compared with the US marketplace, Bayer pharma head Stefan Oelrich tells Scrip.
You may also be interested in...
Bayer Expands Kerendia Program In Competitive Heart Failure Space
The drug maker added three investigator-initiated studies that will enroll more than 9,000 patients to the existing 6,000-patient MOONRAKER program. It has forecast peak sales of
Bayer Sharpens US Focus As Pressure Tightens On Drug Makers
The German company’s two top sellers are marketed by partners in the US, but Bayer will pocket all US sales from its four newest products, at a time when pressures are mounting at home and abroad.
BeiGene To Cash In On Brukinsa’s Potential As Best-In-Class BTKi After CLL Approvals
The Chinese multinational believes Brukinsa could beat competition from the likes of J&J and AstraZeneca to become the BTKi of choice in chronic lymphocytic leukemia, the drug’s latest indication on both sides of the pond.